Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: March 30, 2011
Last updated: October 14, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)